Check Biogen Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$21.2B
EPS (TTM)
15.7406
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.08%
PE Ratio (TTM)
13.86
Industry PE ratio
16.65525641025641
P/B Ratio
13.8632
PEG Ratio
6.2424
EBITDA
3.2B
Revenue (TTM)
10.0B
Profit Margin
15.31%
Return On Equity TTM
9.13%
Track how Biogen Inc. P/E has moved over time to understand its valuation trends.
Biogen Inc. in the last 5 years
Lowest (7.62x)
September 30, 2020
Today (13.86x)
September 18, 2025
Industry (16.66x)
September 18, 2025
Highest (18.33x)
June 30, 2023
Today’s Price to Earnings Ratio: 13.86x
Compare market cap, revenue, PE, and other key metrics of Biogen Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $21.2B | -47.22% | 13.86 | 15.31% | |
BUY | $681.4B | 393.05% | 49.71 | 25.91% | |
BUY | $390.1B | 145.04% | 105.15 | 6.45% | |
BUY | $247.9B | 67.63% | 14.59 | 35.61% | |
BUY | $426.8B | 18.78% | 18.97 | 25.00% |
The Biogen Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Biogen Inc. investment value today
Current value as on today
₹78,282
Returns
Returns from Biogen Inc. Stock
Dollar Returns*
₹4,953 (+4.95%)
Based on 42 analysts
71.43%
Buy
28.57%
Hold
0.00%
Sell
Based on 42 analysts, 71.43% of analysts recommend a 'BUY' rating for Biogen Inc.. Average target price of $170.03
Get share price movements and forecasts by analysts on Biogen Inc..
What analysts predicted
14.79%UPSIDE
Target Price
$170.03
Current Price
$144.89
Analyzed by
42 Analysts
Target
$170.03
Biogen Inc. target price $170.03, a slight upside of 14.79% compared to current price of $144.89. According to 42 analysts rating.
Investment in Biogen Inc. Shares on INDmoney has grown by 175.86% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:175.86% versus previous 30 day period
Search interest for Biogen Inc. Stock has increased by 180% in the last 30 days, reflecting an upward trend in search activity.
Time period: to
Change:180% versus previous 30 day period
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 02 September
Tue, 03:38 PM
-Morgan Stanley analyst maintains Hold rating on Biogen, citing competitive pressures and pricing concerns for Leqembi.
Tue, 05:47 PM
-FDA approves injectable version of Alzheimer's drug Leqembi, developed by Biogen and Eisai.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 2.43B → 2.64B (in $), with an average increase of 8.1% per quarter
Profit Spike
Netprofit is up for the last 2 quarters, 240.5M → 634.8M (in $), with an average increase of 62.1% per quarter
Against Peers
In the last 1 year, Abbvie Inc has given 14.4% return, outperforming this stock by 41.1%
Against Peers
In the last 3 years, Eli Lilly And Company has given 53.3% return, outperforming this stock by 83.7%
Price Dip
In the last 1 year, BIIB stock has moved down by -26.7%
Organisation | Biogen Inc. |
Headquarters | 225 Binney Street, Cambridge, MA, United States, 02142 |
Industry | Health Technology |
CEO | Mr. Christopher A. Viehbacher |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Mr. Christopher A. Viehbacher | President, CEO & Director |
Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer |
Mr. Sean Godbout | Chief Accounting Officer & Global Corporate Controller |
Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer |
Ms. Nicole Murphy | Executive VP and Head of Pharmaceutical Operations & Technology |
Dr. Priya Singhal M.D., M.P.H. | Executive VP & Head of Development |
Ms. Robin C. Kramer | Executive VP & CFO |
Mr. Tim Power M.B.A., Ph.D. | Head of Investor Relations |
Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development |
Ms. Alisha A. Alaimo | President & Head of North America |
Biogen Inc. share price today is $144.89 as on at the close of the market. Biogen Inc. share today touched a day high of $146.68 and a low of $143.39.
Biogen Inc. share touched a 52 week high of $204.18 on and a 52 week low of $110.04 on . Biogen Inc. stock price today i.e. is closed at $144.89,which is 29.04% down from its 52 week high and 31.68% up from its 52 week low.
Biogen Inc. market capitalisation is $0.02T as on .
Indian investors can start investing in Biogen Inc. (BIIB) shares with as little as ₹88.114 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹881.14 in Biogen Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Biogen Inc. share’s latest price of $144.89 as on September 18, 2025 at 1:29 am IST, you will get 0.0690 shares of Biogen Inc.. Learn more about
fractional shares .
Biogen Inc. stock has given -47.22% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?